Cooper Companies (NASDAQ:COO) Price Target Raised to $83.00

Cooper Companies (NASDAQ:COO) had its price target increased by Morgan Stanley from $76.00 to $83.00 in a research report released on Monday morning,Benzinga reports. They currently have an equal weight rating on the medical device company’s stock.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. raised their price target on shares of Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, December 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Cooper Companies in a research note on Monday, December 1st. Stifel Nicolaus set a $95.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Wells Fargo & Company increased their price target on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, December 5th. Finally, Mizuho set a $100.00 price objective on Cooper Companies and gave the company an “outperform” rating in a research report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies currently has an average rating of “Moderate Buy” and an average price target of $90.15.

Cooper Companies Price Performance

Shares of Cooper Companies stock opened at $80.74 on Monday. The business’s fifty day moving average price is $72.95 and its 200 day moving average price is $71.67. Cooper Companies has a twelve month low of $61.78 and a twelve month high of $100.47. The company has a current ratio of 1.89, a quick ratio of 1.13 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $15.82 billion, a P/E ratio of 42.95, a PEG ratio of 2.24 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, research analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has initiated a share buyback plan on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Cooper Companies

In related news, Director Lawrence Erik Kurzius purchased 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The shares were purchased at an average cost of $68.39 per share, with a total value of $136,780.00. Following the completion of the acquisition, the director directly owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. The trade was a 52.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.98% of the company’s stock.

Institutional Trading of Cooper Companies

Several institutional investors have recently added to or reduced their stakes in COO. Horizon Investments LLC boosted its holdings in shares of Cooper Companies by 5.0% in the 1st quarter. Horizon Investments LLC now owns 2,859 shares of the medical device company’s stock valued at $241,000 after buying an additional 136 shares during the period. Wealth Alliance LLC lifted its holdings in Cooper Companies by 4.2% in the second quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock worth $301,000 after acquiring an additional 171 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its stake in Cooper Companies by 1.3% in the third quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock valued at $961,000 after acquiring an additional 175 shares during the period. Pacer Advisors Inc. grew its holdings in shares of Cooper Companies by 0.8% during the third quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock valued at $1,582,000 after purchasing an additional 182 shares during the last quarter. Finally, Citizens Financial Group Inc. RI raised its position in shares of Cooper Companies by 2.7% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock worth $492,000 after purchasing an additional 192 shares during the period. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.